Please wait
Incyte Corporation (INCY) is listed on NMS in the Healthcare sector, with exposure to Biotechnology. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦35T
N/A
16.37
Current price
₦176,505.00
Updated Updated 18h ago
Conviction
78/100
Confidence
Low
Market tone
neutral · 78/100
Entry
Medium · 78/100
Recent price action for INCY, so the page starts with the stock itself before the deeper analysis.
At least one liquidity signal is strong now, though large orders should still be staged.
Valuation view
Looks relatively cheap vs peers
Income view
Income signal not strong yet
Market tone
neutral (78/100) — price action, attention, and recent context all lean here.
Entry view
Medium (78/100) — The company is profitable on the latest reported numbers.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Investors usually follow INCY for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Official filings
0
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
3
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 78/100 while there is no strong bear warning from the current data. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
30.8%
Return on equity
ROA
13.9%
Return on assets
Debt / equity
0.01
Lower is usually safer.
P/B ratio
4.15
Useful for book value support.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦172,950.00
Analyst view
Buy
Analyst target
₦171,477.27
Forecast refresh
Updated 1d ago
Quality score
77
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
US stock catalog seed
Updated 1d ago
Seeded from the built-in US stock catalog for database discovery and later background refresh.
Price points saved
251
Latest market date
2026-07-23
INCY
Incyte Corporation
Price: ₦176,505.00
P/E: 16.366058
Yield: N/A
ABBV
AbbVie Inc.
Price: ₦389,040.00
P/E: 127.76354
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦154,590.00
P/E: 33.352753
Yield: 2.5%
ALGN
Align Technology, Inc.
Price: ₦250,522.50
P/E: 28.248322
Yield: 0.0%
Industry
Biotechnology
Employees
2844
Exchange
NMS
Ticker
INCY
